McIlrath & Eck LLC boosted its stake in shares of Novartis AG (NYSE:NVS) by 42.8% during the first quarter, Holdings Channel reports. The institutional investor owned 514 shares of the company’s stock after purchasing an additional 154 shares during the quarter. McIlrath & Eck LLC’s holdings in Novartis were worth $49,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Truvestments Capital LLC acquired a new position in shares of Novartis in the 1st quarter valued at $25,000. Canton Hathaway LLC acquired a new position in shares of Novartis in the 1st quarter valued at $26,000. Harvest Group Wealth Management LLC acquired a new position in shares of Novartis in the 1st quarter valued at $27,000. Financial Gravity Wealth Inc. acquired a new position in shares of Novartis in the 1st quarter valued at $33,000. Finally, AlphaMark Advisors LLC acquired a new position in shares of Novartis in the 4th quarter valued at $30,000. 11.66% of the stock is currently owned by institutional investors.
Shares of NVS stock traded up $0.50 on Wednesday, hitting $81.23. The stock had a trading volume of 18,509 shares, compared to its average volume of 2,924,542. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $185.98 billion, a PE ratio of 15.94, a P/E/G ratio of 1.94 and a beta of 0.66. Novartis AG has a 1 year low of $63.60 and a 1 year high of $85.08.
Several brokerages have recently commented on NVS. Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target on the stock in a research note on Wednesday, April 24th. Zacks Investment Research lowered Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Morgan Stanley lowered Novartis from an “equal weight” rating to an “underweight” rating and upped their price target for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a research note on Tuesday, January 29th. Five analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $87.57.
COPYRIGHT VIOLATION WARNING: “McIlrath & Eck LLC Buys 154 Shares of Novartis AG (NVS)” was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.themarketsdaily.com/2019/05/15/mcilrath-eck-llc-buys-154-shares-of-novartis-ag-nvs.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Further Reading: No Load Funds
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.